latest news releases from the newsroom
CombiMatrix Molecular Diagnostics Announces the Validation and Launch of the HerScan Test for Assessment of Newly Diagnosed Breast Cancer
MUKILTEO, Wash., Feb. 26, 2008 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that its subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has completed clinical validation and has commercially launched the HerScan(tm) test, the first Bacterial Artificial Chromosome (BAC) Comparative Genomic Hybridization (CGH) array-based test for breast cancer. The HerScan test is designed to detect amplification of the HER2 gene in early breast cancer while simultaneously giving clinicians a complete profile of a patient's tumor genome.
Endocare Sets Date for 2007 Fourth Quarter and Year-End Results Release and Conference Call
IRVINE, Calif., Feb. 26, 2008 (PRIME NEWSWIRE) -- Endocare, Inc. (Nasdaq:ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, plans to issue a press release announcing its financial results for the fourth quarter and year ended December 31, 2007, before the market opens on Tuesday, March 4, 2008, and to host a conference call to be webcast live on the Company's website (www.endocare.com/investors/webcasts.php) at 11:00 a.m. Eastern Time that same day.